Genmab — Juni 2019
-
-
-
-
God morgen

-
ADC Therapeutics says that ADCT-301 showed promising anti-tumour activity preclinically, outperforming Seattle Genetics’ approved ADC drug brentuximab vedotin (Adcetris). https://european-biotechnology.com/up-to-date/latest-news/news/adc-therapeutics-raise-76m-in-series-e-expansion.html
-
ja, og Genmab ramte deres nedre Guiding en af de sidste dage i december
-
hvor konservativ var deres guiding lige sidste år??
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind